Published in Cancer on July 03, 2014
Immune Infiltration and Prostate Cancer. Front Oncol (2015) 0.98
Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. World J Urol (2015) 0.97
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol (2014) 0.94
Pretreatment Neutrophil to Lymphocyte Ratio as a Prognostic Predictor of Urologic Tumors: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2015) 0.89
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol (2016) 0.89
Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep (2015) 0.89
Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.86
Current Status of Hepatic Arterial Infusion Chemotherapy. Liver Cancer (2015) 0.85
Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients. Sci Rep (2016) 0.83
Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy. Medicine (Baltimore) (2015) 0.83
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysis. Medicine (Baltimore) (2016) 0.81
Regulation of prostate cancer progression by the tumor microenvironment. Cancer Lett (2016) 0.81
Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.80
A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Med (2015) 0.80
Elevated preoperative neutrophil-to-lymphocyte ratio is associated with poor prognosis in gastrointestinal stromal tumor patients. Onco Targets Ther (2016) 0.79
A Novel and Validated Inflammation-Based Score (IBS) Predicts Survival in Patients With Hepatocellular Carcinoma Following Curative Surgical Resection: A STROBE-Compliant Article. Medicine (Baltimore) (2016) 0.79
Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy in localized prostate cancer. Prostate Cancer Prostatic Dis (2016) 0.77
Neutrophil to lymphocyte ratio is an independent prognostic factor in patients with recurrent or metastatic head and neck squamous cell cancer. Mol Clin Oncol (2015) 0.77
Cancer-related inflammation: an emerging prognostic domain in metastatic castration-resistant prostate carcinoma. Cancer (2014) 0.76
Association of the neutrophil-to-lymphocyte ratio and prostate cancer detection rates in patients via contemporary multi-core prostate biopsy. Asian J Androl (2015) 0.75
Blood-based gene expression profiling in castrate-resistant prostate cancer. BMC Med (2015) 0.75
Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms. Oncotarget (2016) 0.75
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review. J Inflamm (Lond) (2016) 0.75
Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS). PLoS One (2017) 0.75
Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. BMC Urol (2017) 0.75
The prognostic significance of postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for localized prostate cancer. Oncotarget (2016) 0.75
Prognostic value of parameters derived from white blood cell and differential counts in patients receiving palliative radiotherapy. Mol Clin Oncol (2016) 0.75
Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer (2017) 0.75
Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer. Clin Transl Oncol (2017) 0.75
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Drug penetration in solid tumours. Nat Rev Cancer (2006) 9.80
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer (2005) 3.58
Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol (2012) 3.56
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol (2011) 3.46
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol (2008) 3.41
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res (2007) 3.41
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA (2003) 3.36
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol (2009) 3.21
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol (2013) 2.92
Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer (2008) 2.89
Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell (2009) 2.85
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res (2012) 2.81
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol (2007) 2.79
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol (2009) 2.66
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res (2009) 2.62
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res (2007) 2.61
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol (2013) 2.57
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst (2013) 2.54
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol (2010) 2.47
Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol (2005) 2.42
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res (2005) 2.33
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab (2011) 2.32
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
Placebo effects in oncology. J Natl Cancer Inst (2003) 2.23
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst (2007) 2.14
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol (2011) 2.14
When are "positive" clinical trials in oncology truly positive? J Natl Cancer Inst (2010) 2.09
Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res (2009) 2.04
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol (2012) 1.98
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol (2009) 1.95
Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. J Gen Intern Med (2006) 1.88
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int (2008) 1.88
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res (2007) 1.87
Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86
Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol (2008) 1.85
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res (2007) 1.84
Screening trials are even more difficult than we thought they were. J Natl Cancer Inst (2002) 1.76
MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials (2011) 1.71
Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol (2007) 1.69
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin (2011) 1.68
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res (2011) 1.64
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol (2003) 1.63
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.62
The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res (2006) 1.58
Trials in palliative treatment--have the goal posts been moved? Lancet Oncol (2008) 1.57
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer (2011) 1.55
Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Expert Opin Investig Drugs (2011) 1.53
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. Prostate (2013) 1.52
Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol (2010) 1.51
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol (2009) 1.50
Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. J Pain Symptom Manage (2012) 1.50
CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol (2008) 1.49
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res (2005) 1.48
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res (2008) 1.47
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J (2009) 1.46
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer (2009) 1.45
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol (2011) 1.43
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res (2010) 1.42
Mathematics in the realm of lapatinib: 500 + 500 = 1,500? J Clin Oncol (2008) 1.42
Company stock prices before and after public announcements related to oncology drugs. J Natl Cancer Inst (2011) 1.42